Erratum: Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. Ibuprofen alone for reduction of gastric and duodenal ulcers (American Journal of Gastroenterology (2012) 107 (379-386) DOI:10.1038/ajg.2011.443);Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers

American Journal of Gastroenterology

Volumn 107, Issue 3, 2012, Pages 379-386

  Laine, Loren ^a   Kivitz, Alan J ^b   Bello, Alfonso E ^c   Grahn, Amy Y ^d   Schiff, Michael H ^e   Taha, Ali S ^f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Altoona Center for Clinical Research   (United States)

^c ILLINOIS BONE AND JOINT INSTITUTE   (United States)

^d Horizon Therapeutics   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FAMOTIDINE PLUS IBUPROFEN; HZT 501; IBUPROFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; FEMALE; GASTROINTESTINAL BIOPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ULCER; TABLET;

EID: 84857885367     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.244     Document Type: Erratum

References (23)

1. Kaufman DW, Kelly JP, Rosenberg L et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287: 337-44. (Pubitemid 34251967)
2. Paulose-Ram R, Hirsch R, Dillon C et al. Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Safety 2003; 12: 315-26. (Pubitemid 36700608)
3. Wilcox CM, Allison J, Benzuly K et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol 2006; 4: 1082-9.
4. Chan FKL, Abraham NS, Scheiman JS et al. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the first international working party on gastrointestinal and cardiovascular effects of nonsteroidal anti-inflammatory drugs and anti-platelet agents. Am J Gastroenterol 2008; 103: 2908-18.
5. Rostom A, Moayyedi P, Hunt R et al. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009; 29: 481-96.
6. Lanza FL, Chan FKL, Quigley EMM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728-38.
7. Rostom A, Dube C, Wells G et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002: 4: CD002296.
8. Abraham NS, El-Serag HB, Johnson ML et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal antiinflammatory drugs. Gastroenterology 2005; 129: 1171-8. (Pubitemid 41446857)
9. Laine L, Margolis J, Brown K. Use of GI protective agents and COX-2 selective inhibitors in 14394624 U.S. patients taking NSAIDs. Gastroenterology 2004; 126 (Suppl 2): A36-7.
10. Goldstein JL, Howard KB, Walton SM et al. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006; 4: 1337-45.
11. Abraham NS, Hartman C, Castillo D et al. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol 2008; 103: 323-32. (Pubitemid 351248716)
12. Sturkenboom MCJM, Burke TA, Tangelder MJD et al. Adherence to proton pump inhibitors or H 2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003; 18: 1137-47. (Pubitemid 38021600)
13. van Soest EM, Sturkenboom MCJM, Dieleman JP et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007; 26: 265-75. (Pubitemid 46985490)
14. Westfall PH, Tobias RD, Rom D et al. Multiple Comparisons and Multiple Tests Using the SAS System. SAS Institute: Cary, NC, 1999.
15. Taha AS, Hudson N, Hawkey CJ et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334: 1435-9. (Pubitemid 26157439)
16. Tidmarsh G, Rodriguez SB. Famotidine (FAM) three times daily (tid) produces better gastric suppression and control than does twice daily (bid) administration of the same total daily dose. Gastroenterology 2009; 136 (Suppl 1): A611-2.
17. Tidmarsh G, Rodriguez SB. HZT-501, a novel combination of ibuprofen (Ibu) and famotidine (FAM), provides pharmacokinetics comparable to that of commercially available Ibu and Fam in a patient-friendly dosing form: evaluation in healthy and renally impaired subjects. Gastroenterology 2009; 136 (Suppl 1): A612.
18. Van Groenendael JHLM, Markusses HM, Dijkmans BAC et al. The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 1996; 15: 450-6. (Pubitemid 26319789)
19. Bijlsma JW. Treatment of endoscopy-negative NSAID-induced upper gastrointestinal symptoms with cimetidine: an international multicentre collaborative study. Aliment Pharmacol Ther 1988; 2 (Suppl 1): 75-83.
20. Rostom A, Muir K, Dube C et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane collaboration systematic review. Clin Gastroenterol Hepatol 2007; 5: 818-28.
21. Schnitzer TJ, Burmester GR, Mysler E et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet 2004; 364: 665-74. (Pubitemid 39140622)
22. Chan FKL, Lanas A, Scheiman J et al. Celecoxib vs. omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomized trial. Lancet 2010; 376: 173-9.
23. Humphries TJ. Famotidine: a notable lack of drug interactions. Scand J Gastroenterol 1987; 22 (Suppl 134): 55-60. (Pubitemid 17112439)